Allergic Rhinitis
Conditions
Brief summary
The purpose of the trial is to compare the efficacy and safety of sublingual seasonal and annual immunotherapy in children with allergic rhinitis allergic to grass pollens.
Detailed description
Allergen immunotherapy is currently the only one method of cause treatment of the IgE-dependent allergic diseases. Sublingual immunotherapy (SLIT) is the method which allows to give allergens via alternative oral route in patients home. Due to the possibility of avoiding injection this therapy allows to have better relationship with patient, and reduce the costs of therapy thanks to reducing the numbers of visits in out-patient clinic.However efficacy and safety of sublingual immunotherapy are still important issues, especially in children. The purpose of trial is to compare the efficacy and safety of sublingual seasonal and annual immunotherapy in children with allergic rhinitis allergic to grass pollens.
Interventions
BIOLOGICALsublingual allergen extract
Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
BIOLOGICALplacebo
Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
Sponsors
Medical University of Lodz
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children with seasonal allergic rhinitis, allergic to grass pollens, first diagnosed at least 2 years before inclusion into the study
Exclusion criteria
* Active upper respiratory tract infection within 3 weeks before the study and acute sinus disease requiring antibiotic treatment within 1 month before the study * Allergic rhinitis hospitalisation during the 3 months before the first visit. * Additional criteria were other clinically significant pulmonary, hematologic, hepatic, gastrointestinal, renal, endocrine, neurologic, cardiovascular, and/or psychiatric diseases or malignancy that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator. * Excluded medications were systemic corticosteroids. * Patients who were receiving immunotherapy were also excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical symptoms of allergic rhinitis (Pediatric Quality of Life Questionnaire) | Following visits after starting the study: at 6 months, 9 months, 12 months, 18 months, 21 months, 24 months. | Visit 2 (6 months after starting the study), visit 3 (9 months after starting the study), visit 4 (12 months after starting the study), visit 5 (18 months after starting the study), visit 6 (21 months after starting the study), visit 7 (24 months after starting the study). |
Secondary
| Measure | Time frame |
|---|---|
| Change of percent of regulatory lymphocytes in the peripheral blood. | at baseline and at the end of the second season (22 months interval) |
| non-specific bronchial hyperreactivity with methacholine (PC20M), specific nasal provocation test. | at the end of the first and second season of the study (12 months interval) |
Countries
Poland
Outcome results
None listed